News

Company News & Events

ORYZON First Quarter 2020 Results and Corporate Update

11 May 2020

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter of 2020 and provided an update on recent developments.

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said, "Oryzon continued to advance its clinical programs in the first quarter. We are encouraged by the exciting signals of clinical efficacy observed in both our iadademstat oncology and vafidemstat neurology programs, combined with good safety and tolerability profiles.”

 

Click here to see the full Press Release

 

Posted In: 
News
Investors

Share this story